Literature DB >> 26048902

Decision-theoretic designs for small trials and pilot studies: A review.

Siew Wan Hee1, Thomas Hamborg2, Simon Day3, Jason Madan2, Frank Miller4, Martin Posch5, Sarah Zohar6, Nigel Stallard2.   

Abstract

Pilot studies and other small clinical trials are often conducted but serve a variety of purposes and there is little consensus on their design. One paradigm that has been suggested for the design of such studies is Bayesian decision theory. In this article, we review the literature with the aim of summarizing current methodological developments in this area. We find that decision-theoretic methods have been applied to the design of small clinical trials in a number of areas. We divide our discussion of published methods into those for trials conducted in a single stage, those for multi-stage trials in which decisions are made through the course of the trial at a number of interim analyses, and those that attempt to design a series of clinical trials or a drug development programme. In all three cases, a number of methods have been proposed, depending on the decision maker's perspective being considered and the details of utility functions that are used to construct the optimal design.
© The Author(s) 2015.

Entities:  

Keywords:  Bayesian decision theory; optimal clinical trial design; phase II clinical trials; utility functions

Mesh:

Year:  2015        PMID: 26048902      PMCID: PMC4876428          DOI: 10.1177/0962280215588245

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  66 in total

1.  Optimal sample sizes for phase II clinical trials and pilot studies.

Authors:  Nigel Stallard
Journal:  Stat Med       Date:  2011-11-03       Impact factor: 2.373

2.  The value of information and optimal clinical trial design.

Authors:  Andrew R Willan; Eleanor M Pinto
Journal:  Stat Med       Date:  2005-06-30       Impact factor: 2.373

3.  Adaptive, group sequential and decision theoretic approaches to sample size determination.

Authors:  Cyrus R Mehta; Nitin R Patel
Journal:  Stat Med       Date:  2006-10-15       Impact factor: 2.373

4.  Value of information and pricing new healthcare interventions.

Authors:  Andrew R Willan; Simon Eckermann
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

5.  Approximately optimal designs for phase II clinical studies.

Authors:  N Stallard
Journal:  J Biopharm Stat       Date:  1998-07       Impact factor: 1.051

6.  Designing a series of decision-theoretic phase II trials in a small population.

Authors:  Siew Wan Hee; Nigel Stallard
Journal:  Stat Med       Date:  2012-08-24       Impact factor: 2.373

7.  Evaluation of early efficacy endpoints for proof-of-concept trials.

Authors:  Cong Chen; Linda Sun; Chih-Lin Li
Journal:  J Biopharm Stat       Date:  2013-03-11       Impact factor: 1.051

8.  A decision theory approach to phase II clinical trials.

Authors:  M Staquet; R Sylvester
Journal:  Biomedicine       Date:  1977-07

9.  A bayesian approach to the design of phase II clinical trials.

Authors:  R J Sylvester
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

10.  A Bayesian decision-theoretic sequential response-adaptive randomization design.

Authors:  Fei Jiang; J Jack Lee; Peter Müller
Journal:  Stat Med       Date:  2013-01-13       Impact factor: 2.373

View more
  7 in total

1.  To add or not to add a new treatment arm to a multiarm study: A decision-theoretic framework.

Authors:  Kim May Lee; James Wason; Nigel Stallard
Journal:  Stat Med       Date:  2019-05-21       Impact factor: 2.373

Review 2.  Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small Patients.

Authors:  Robert A Beckman; Zoran Antonijevic; Mercedeh Ghadessi; Heng Xu; Cong Chen; Yi Liu; Rui Tang
Journal:  Paediatr Drugs       Date:  2022-10-15       Impact factor: 3.930

3.  Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.

Authors:  Michael Pearce; Siew Wan Hee; Jason Madan; Martin Posch; Simon Day; Frank Miller; Sarah Zohar; Nigel Stallard
Journal:  BMC Med Res Methodol       Date:  2018-02-08       Impact factor: 4.615

4.  Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution.

Authors:  Siew Wan Hee; Nicholas Parsons; Nigel Stallard
Journal:  Biom J       Date:  2017-07-26       Impact factor: 2.207

5.  Experimental replications in animal trials.

Authors:  Florian Frommlet; Georg Heinze
Journal:  Lab Anim       Date:  2020-03-05       Impact factor: 2.471

6.  Determination of the optimal sample size for a clinical trial accounting for the population size.

Authors:  Nigel Stallard; Frank Miller; Simon Day; Siew Wan Hee; Jason Madan; Sarah Zohar; Martin Posch
Journal:  Biom J       Date:  2016-05-17       Impact factor: 2.207

Review 7.  Recent advances in methodology for clinical trials in small populations: the InSPiRe project.

Authors:  Tim Friede; Martin Posch; Sarah Zohar; Corinne Alberti; Norbert Benda; Emmanuelle Comets; Simon Day; Alex Dmitrienko; Alexandra Graf; Burak Kürsad Günhan; Siew Wan Hee; Frederike Lentz; Jason Madan; Frank Miller; Thomas Ondra; Michael Pearce; Christian Röver; Artemis Toumazi; Steffen Unkel; Moreno Ursino; Gernot Wassmer; Nigel Stallard
Journal:  Orphanet J Rare Dis       Date:  2018-10-25       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.